Analysts Set Arvinas, Inc. (NASDAQ:ARVN) Target Price at $13.24

Shares of Arvinas, Inc. (NASDAQ:ARVN) have earned a consensus rating of “Hold” from the twenty analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $13.4706.

ARVN has been the topic of several analyst reports. Barclays upped their price objective on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price target (up from $16.00) on shares of Arvinas in a research report on Wednesday. Wall Street Zen upgraded Arvinas from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. Wells Fargo & Company cut their price objective on Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling meaningful upside versus current levels. Read More.
• Positive Sentiment: HC Wainwright raised longer‑range earnings projections for FY2028–FY2030 (FY2028 to $3.09, FY2029 to $1.76, FY2030 to $5.60), implying stronger late‑cycle profitability if clinical/program milestones are met. Read More.
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Ikarian among buyers), which can support liquidity and indicate some investor confidence in the pipeline. Read More.
• Neutral Sentiment: Street consensus remains mixed (MarketBeat shows a “Hold” consensus with a $13.47 average target), so analyst moves are not uniform — upgrades from some firms may not sway broader sentiment. Read More.
• Neutral Sentiment: Reported short‑interest figures in recent updates appear to be erroneous (showing 0 shares/NaN), so short‑interest/read‑through risk is unclear until corrected data is published. (data report)
• Negative Sentiment: HC Wainwright sharply cut near‑term estimates (Q1–Q4 2026 and FY2026/FY2027 EPS downgraded), lowering expected profitability this year and next — a near‑term negative catalyst for the stock. Read More.
• Negative Sentiment: Q4 2025 results were a clear negative: EPS and revenue missed materially (reported -$1.10 EPS vs. -$0.55 expected; revenue $9.5M vs. $37.3M expected), which is the primary driver pressuring the share price. Read More.
• Negative Sentiment: Insider sales: CEO Randy Teel and CAO David Loomis sold shares on Feb. 23 (modest reductions). Insider selling can be perceived negatively even when routine; filings: Read More., Read More.

Insider Buying and Selling at Arvinas

In related news, CFO Andrew Saik sold 5,134 shares of Arvinas stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the transaction, the chief financial officer directly owned 159,267 shares of the company’s stock, valued at $1,893,684.63. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Noah Berkowitz sold 5,685 shares of the company’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $67,594.65. Following the transaction, the insider owned 163,938 shares in the company, valued at approximately $1,949,222.82. This trade represents a 3.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 22,132 shares of company stock worth $264,741 over the last ninety days. Corporate insiders own 4.73% of the company’s stock.

Institutional Investors Weigh In On Arvinas

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Monaco Asset Management SAM grew its stake in shares of Arvinas by 185.6% during the second quarter. Monaco Asset Management SAM now owns 900,936 shares of the company’s stock valued at $6,631,000 after purchasing an additional 585,477 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock worth $10,498,000 after buying an additional 1,267,593 shares in the last quarter. Campbell & CO Investment Adviser LLC lifted its holdings in Arvinas by 307.7% during the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 223,576 shares of the company’s stock worth $1,905,000 after buying an additional 168,744 shares in the last quarter. Nordea Investment Management AB boosted its position in Arvinas by 28.7% in the 3rd quarter. Nordea Investment Management AB now owns 557,742 shares of the company’s stock valued at $4,730,000 after buying an additional 124,254 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Arvinas in the 2nd quarter valued at $390,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Price Performance

Shares of Arvinas stock opened at $13.27 on Wednesday. Arvinas has a 52-week low of $5.90 and a 52-week high of $18.93. The firm has a market capitalization of $848.75 million, a PE ratio of -10.37 and a beta of 1.88. The company’s fifty day moving average price is $12.48 and its two-hundred day moving average price is $10.60.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The business had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. Arvinas’s revenue was down 84.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.63) earnings per share. Analysts predict that Arvinas will post -3.81 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.